Skip to main content

Table 3 Associations of differences between Δage (per 5 years) according to different predictors of DNAmage with all-cause and cause-specific mortality by sex

From: Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort

  Number of events; % Predictor Cox model 1a
(Hazard ratios)
Cox model 1b
(Hazard ratios)
All-cause mortality     
Women 251; 41.7 DNAmage (Horvath) 1.27 (1.07–1.52) 1.24 (1.02–1.52)
   DNAmage (Hannum) 1.19 (0.94–1.51) 1.05 (0.82–1.36)
Men 351; 58.3 DNAmage (Horvath) 1.23 (1.05–1.43) 1.28 (1.09–1.51)
   DNAmage (Hannum) 1.14 (0.94–1.40) 1.14 (0.92–1.41)
Cancer mortality     
Women 95; 40.4 DNAmage (Horvath) 1.20 (0.93–1.54) 1.21 (0.88–1.65)
   DNAmage (Hannum) 1.02 (0.69–1.50) 0.89 (0.58–1.36)
Men 140; 59.6 DNAmage (Horvath) 1.18 (0.95–1.47) 1.25 (0.98–1.59)
   DNAmage (Hannum) 1.08 (0.80–1.46) 1.12 (0.79–1.58)
CVD mortality     
Women 80; 41.2 DNAmage (Horvath) 1.17 (0.91–1.51) 1.13 (0.82–1.55)
   DNAmage (Hannum) 1.21 (0.85–1.72) 1.01 (0.64–1.61)
Men 114; 58.8 DNAmage (Horvath) 1.25 (0.98–1.59) 1.29 (0.99–1.68)
   DNAmage (Hannum) 1.06 (0.77–1.47) 1.00 (0.71–1.42)
  1. CVD cardiovascular disease
  2. aModel 1: adjusted for chronological age (continuous), sex, batch effects, and leucocyte distribution
  3. bModel 2: additionally adjusted for educational level, history of cancer diseases, history of CVD, hypertension, diabetes mellitus, smoking status (never/former vs. current), and Body Mass Index (continuous)